CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of “Moderate Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has been given a consensus rating of “Moderate Buy” by the fourteen research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $61.4167.

A number of research analysts have recently commented on CGON shares. Guggenheim started coverage on shares of CG Oncology in a research report on Tuesday, October 7th. They set a “buy” rating and a $90.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on CG Oncology from $41.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, September 26th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a research note on Monday, September 15th. Royal Bank Of Canada raised their price target on CG Oncology from $53.00 to $61.00 and gave the company an “outperform” rating in a report on Monday, November 17th. Finally, Wedbush started coverage on CG Oncology in a research report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target for the company.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.43, for a total value of $41,430.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Winthrop Capital Management LLC bought a new position in CG Oncology in the second quarter valued at $38,000. Strengthening Families & Communities LLC purchased a new position in shares of CG Oncology in the 3rd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after purchasing an additional 398 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of CG Oncology by 15.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after buying an additional 433 shares in the last quarter. Finally, CWM LLC lifted its position in CG Oncology by 193.5% in the 2nd quarter. CWM LLC now owns 6,193 shares of the company’s stock worth $161,000 after buying an additional 4,083 shares during the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Stock Down 1.2%

Shares of CGON opened at $41.93 on Friday. CG Oncology has a twelve month low of $14.80 and a twelve month high of $46.01. The stock has a market cap of $3.38 billion, a PE ratio of -20.55 and a beta of 1.35. The business’s 50-day moving average price is $41.18 and its 200-day moving average price is $35.09.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.57) EPS for the quarter, meeting analysts’ consensus estimates of ($0.57). The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.07 million. Analysts expect that CG Oncology will post -1.31 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.